News

AVP-21D9 is presently in a randomised, double-blind, placebo-controlled, dose escalation Phase I clinical study involving 50 healthy volunteers designed to evaluate the safety and pharmacokinetics of the product

The funding will allow Achillion Pharmaceuticals to further advance its portfolio of HCV clinical candidates, as well as allow it to capitalise certain antibacterial assets. Achillion senior vice

The grants were awarded in recognition of its two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon(R) adjuvant. Antigenics

Bromodeoxyuridine (BrdU) – an analog of the DNA base thymidine – is a reagent commonly used in the detection of proliferating cells in living tissues and tissue samples.

DURECT has posted a net loss of $4.65m for the third quarter 2010, or $0.05 loss per diluted share, compared to net loss of $5.54m, or $0.07 loss

To define the potential coverage of 4CMenB against circulating MenB strains, the research investigators examined the characteristics of a collection of 124 MenB strains using pooled sera from

ALN-HTT consists of an RNAi therapeutic targeting huntingtin, the gene responsible for Huntington’s disease, that is being developed for delivery to the central nervous system (CNS) using an

Under the Act, $1bn was earmarked for qualifying therapeutic discovery projects that treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and

Huber said that the license granted by California’s Department of Public Health, Food and Drug Branch represents a milestone for the continued development of Huber’s Health & Nutrition